Salute e Benessere

Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety…

Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer's Disease to Proceed at Highest Investigated DoseInterim analysis completed, with 600mg twice daily dosing unanimously selected by independent DSMB as final dose for remainder of Phases 2a and 2b of VIVA-MIND study in U.S.Decision follows 2022 DSMB determination for VIVIAD Phase 2 EU study to proceed...
Nasdaq GlobeNewswire
23/10/2023

Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for…

Dupixent ®(dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce the role of type 2 inflammation in EoE and the importance of targeting both IL-4 and IL-13 pathwayssBLA for Dupixent to treat...
Nasdaq GlobeNewswire
22/10/2023

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in…

Media Release TIVDAK demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congressResults from innovaTV 301 intended to serve as pivotal confirmatory trial for U.S. accelerated approval and to support global regulatory applications COPENHAGEN, Denmark, and BOTHELL, Wash.; October 22, 2023 –Genmab A/S(Nasdaq: GMAB) andSeagen Inc.(Nasdaq:...
Nasdaq GlobeNewswire
22/10/2023

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3…

Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01 positive patients with previously untreated metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 21 October 2023)ImmunocoreHoldings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell...
Nasdaq GlobeNewswire
21/10/2023

F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in…

An overall success rate of 28.7% was seen at day 42, the primary endpoint, and 27.2% at day 84, as determined by a data review committee (DRC) using the EORTC-MSG criteria The success rate rose to 75.2% at day 42 and 63.4% at day 84 when stable disease was counted as successAll-cause mortality (ACM) at day 42 and day 84 was 11.4% and 15.8%, respectively MANCHESTER, United Kingdom and OSAKA, Japan, Oct.21, 2023(GLOBE NEWSWIRE) -- F2G Ltd. and Shionogi & Co., Ltd., today...
Nasdaq GlobeNewswire
21/10/2023

Sharjah Government Pavilion showcased sustainable and proactive projects at…

During his tour, Sheikh Saud reviewed the remarkable achievements presented by the Dubai Digital Government, Ajman Digital Government, Fujairah Government, Abu Dhabi Government, Telecommunications and Digital Government Regulatory Authority, Etisalat by e&, and Du. He gained insights into the latest projects and technical solutions provided by these entities towards supporting digital transformation across various sectors, including healthcare, education, environment, and culture...
PR Newswire
20/10/2023

Mdxhealth's New Share Capital Amount and New Number of Shares

NEWS RELEASE - REGULATED INFORMATION October 20, 2023 , 4:00 PM EDT / 22:00 CETMdxhealth's New Share Capital Amountand New Number of SharesIRVINE, CA, and HERSTAL, BELGIUM– October 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (" mdxhealth " or the " Company "), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares...
Nasdaq GlobeNewswire
20/10/2023

Zealand Pharma major shareholder announcement: Polar Capital

Company announcement – No. 37 / 2023 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 20 October 2023–Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 20 October 2023 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:...
Nasdaq GlobeNewswire
20/10/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven, BELGIUM, Boston, MA, US – October 20, 2023 – 08.00 PM CET– In...
Nasdaq GlobeNewswire
20/10/2023

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – October 20, 2023 – 8.00 PM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received transparency notifications as follows: Oxurion received a first transparency notification on October 19, 2023, from Atlas...
Nasdaq GlobeNewswire
20/10/2023

Innocan Pharma Announces Closing of Second and Final Tranche of Financing

The Offering is led by Research Capital Corporation as sole agent and sole bookrunner (the "Agent"). The Offering is led by Research Capital Corporation as sole agent and sole bookrunner (the " Agent "). Each Unit is comprised of one common share of the Company (a " Common Share ") and one purchase warrant of the Company (a " Warrant "). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of$0.36for a period of…
PR Newswire
20/10/2023

Velico Medical launches Blood Center Education Program with South Texas Blood &…

Velico's BCEP is designed to generate deep customer feedback on the commissioning and operational aspects of the FrontlineODP™ system for spray drying plasma. Velico's BCEP is designed to generate deep customer feedback on the commissioning and operational aspects of the FrontlineODP™ system for spray drying plasma. FrontlineODP is expected to be an easy to produce, easy to use, point-of-care plasma product for transfusion in settings where current plasma products (most often frozen) are...
PR Newswire
20/10/2023

Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment…

Coming off of a late-2022 Fast Track Designation (FTD) from the FDA for the treatment of advanced/metastatic pancreatic cancer with its flagship asset, pelareorep, biotechnology company Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) has now been selected to be part of the Precision PromiseSM Phase 3 platform trial by PanCAN. Coming off of a late-2022 Fast Track Designation (FTD) from the FDA for the treatment of advanced/metastatic pancreatic cancer with its flagship asset, pelareorep,...
PR Newswire
20/10/2023

CORRECTION: Bioretec Ltd's Board of Directors has decided on a new option…

A maximum total of 1,000,000 option rights will be issued, and they will entitle their owners to subscribe for a maximum total of 1,000,000 new shares in the company. The option rights will be issued free of charge. Shares can be subscribed to on the basis of the option rights as follows: A maximum total of 1,000,000 option rights will be issued, and they will entitle their owners to subscribe for a maximum total of 1,000,000 new shares in the company. The option rights will be issued free of...
PR Newswire
20/10/2023

Biopsy Devices Market Worth $12.6 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132886515 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132886515 Browse in-depth TOC on "Biopsy Devices Market"120 - Tables 60 - Figures 300 - Pages Biopsy Devices Market Scope: Technology segment to register significant growth rate over the forecast period of 2023-2028 Based on product, the global biopsy devices market is...
PR Newswire
20/10/2023

InDex Pharmaceuticals has been granted a new patent for cobitolimod in South…

Corresponding patent applications have previously been granted in Europe and Hong Kong and filed in additional strategically important patent territories globally. Corresponding patent applications have previously been granted inEuropeandHong Kongand filed in additional strategically important patent territories globally. For more information: Jenny Sundqvist, CEO Phone: +46 8 122 038 50 E-mail:jenny.sundqvist@indexpharma.com Johan Giléus, Deputy CEO and CFO Phone: +46 8...
PR Newswire
20/10/2023

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial…

Conference Call & Webcast Conference Call & Webcast Date: Friday, November 3, 2023 Time: 8:30 a.m. ET Dial-In – North American Toll-Free:(888) 664-6383 Dial-In – International: (416) 764-8650 RapidConnect: to join the conference call without operator assistance, pleaseclick here Conference ID(if needed) :6026-0546 Webcast: pleaseclick here A webcast of the call will also be available on the Investor Relations page of Oncolytics' website,...
PR Newswire
20/10/2023

Cancer Prevention Scholars and Climate Crisis Experts from Korea, US and Japan…

Professor Thomas Seyfried of Boston College, USA, who gave the keynote speech, emphasized that "cancer is a metabolic disease, not a disease caused by genetic mutation" and proposed a new approach to treating cancer and preventing recurrence. Next, at the book concert, Director Takashi Funato, author of the book 'Lifestyle Habits to Cure Cancer', director of Reborn Horado, Japan, spoke. As a former surgeon, he shared his experiences of witnessing patients recovering from a cancer…
PR Newswire
20/10/2023

Bioretec Ltd's Board of Directors has decided on a new option program 2023-1

The subscription period for the shares ends on 31 December 2029. The subscription period for the shares ends on31 December 2029. The shares that are subscribed with the option rights to be issued will account for a total maximum of approximately 4.9 % of all the company's shares and votes after possible share subscriptions. As a result of the share subscriptions made with the option rights, the number of shares in the company may increase by a total maximum of 1,000,000 shares. The...
PR Newswire
20/10/2023

The 14th China (Taizhou) International Medical Expo Opens, Empowering the Growth…

Taizhou, in collaboration with international organizations, multinational enterprises, and academic institutions, is establishing research centers and production bases, creating a city that leads in health innovation. Currently, China Medical City has successfully established major innovation platforms such as the National Technology Innovation Center for Veterinary Biological Products (Taizhou), the Biopharmaceutical Innovation Research Institute of the Chinese Academy of Sciences (CAS) Dalian…
PR Newswire
20/10/2023

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of…

Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors, node-negative disease and those who are 65 or older 1 The data reinforce previously presented results which reported that investigational use of Kisqali ®(ribociclib) plus endocrine therapy (ET) significantly lowered the risk of cancer recurrence across a broad population of patients...
Nasdaq GlobeNewswire
20/10/2023

The 14th China (Taizhou) International Medical Expo Opens, Empowering the Growth…

Taizhou, in collaboration with international organizations, multinational enterprises, and academic institutions, is establishing research centers and production bases, creating a city that leads in health innovation. Currently, China Medical City has successfully established major innovation platforms such as the National Technology Innovation Center for Veterinary Biological Products (Taizhou), the Biopharmaceutical Innovation Research Institute of the Chinese Academy of Sciences (CAS) Dalian…
PR Newswire
20/10/2023

Nexstim Has Won a Tender Process Resulting in a Procurement Decision

Press release, Helsinki, 20 October 2023 at 9 AM (EEST) Nexstim Has Won a Tender Process Resulting in a Procurement DecisionNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has won a tender process resulting in a procurement decision for an NBS 5 System in Finland.The customer is new to Nexstim in psychiatric applications. This specific NBS (Navigated Brain Stimulation) System 5 includes both diagnostic and therapeutic capabilities. This means that the system is suitable…
Nasdaq GlobeNewswire
20/10/2023

Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and…

Press ReleaseNicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones Third quarter 2023 U.S. prescriptions for VYZULTA ®increased by 22% over third quarter 2022 NCX 470 Phase 3 Denali clinical trial over 65% randomizedNet revenue €1.7 million for first half 2023 and €1.1 million for third quarter 2023Cash of €14.6 million on September 30, 2023October 20, 2023 – release at 7:30 am CETSophia Antipolis, France...
Nasdaq GlobeNewswire
20/10/2023
Altri  Comunicati